TheStreet’s Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple. Celgene has been in a decline but the company could have $15-$16 earnings power in a couple of years, says Cramer, and it is cheaper than Merck and Pfizer. Cramer is also watching Salesforce.com, which has seen a shrinking multiple since it reported a great quarter. If Celgene and Salesforce turn around, money will come back to high-growth from value names.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
